Botanix Pharmaceuticals Explained

Botanix Pharmaceuticals Limited
Type:Listed Public Company
Location:Perth, Western Australia, and Philadelphia, USA
Area Served:Global
Industry:Biotechnology
Products:BTX 1503 For the treatment of moderate to severe acneBTX 1702 For the treatment of rosaceaBTX 1204A For the treatment of moderate atopic dermatitisBTX 1801 For use in a variety of antimicrobial applications

Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic[1] cannabinoid[2] company, focusing on the compound Cannabidiol.[3] The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex,[4] for direct skin delivery of active pharmaceuticals which is utilised in all of their programs.

Research

Botanix Pharmaceuticals product pipeline[5] currently includes four programs for treatment of serious skin diseases:

Dermatology

Antimicrobial

Notes and References

  1. Web site: Synthetic cannabinoids.
  2. Web site: Cannabinoid.
  3. Web site: Cannabidiol.
  4. Web site: Technology – Botanix Pharmaceuticals.
  5. Web site: Pipeline – Botanix Pharmaceuticals.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Botanix Pharmaceuticals".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.